- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05720637
The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder
February 18, 2024 updated by: Xiaomei Shao
The Efficacy and Cerebral Mechanism of Intradermal Acupuncture for Major Depressive Disorder: a Study Protocol for a Randomized Controlled Trial
Major depressive disorder (MDD) is highly prevalent, affecting nearly 4% of the global population.
Pharmacotherapy is the frontline treatment recommended by the guideline, but it also has some limitations such as delayed onset, inadequate response, and drug resistance.
Intradermal acupuncture (IA) is a method of using short indwelling needles retained under the skin to produce continuous stimulation for long-term efficacy.
It has been reported that IA combination medication appears to be more valuable than medication alone in the treatment of MDD, however, there is a lack of high-quality clinical evidence.While several studies have proposed that manual or electroacupuncture can improve MDD symptoms by modulating brain networks, the cerebral mechanism of IA as superficial acupuncture for MDD has not been reported.
Hence, investigators designed a multicentre randomized controlled trial to assess the clinical efficacy and safety of IA for MDD and preliminarily explore the potential therapeutic mechanisms for IA by functional magnetic resonance imaging (fMRI) .
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
A total of 120 patients with MDD who meet the inclusion criteria will be included in the study.
Participants will be randomly assigned 1:1:1 to the waiting list group (patients in this group will be treated with selective 5-hydroxytryptamine reuptake inhibitors (SSRIs) only), sham intradermal acupuncture combined with SSRIs (SIA) group and active intradermal acupuncture combined with SSRIs (AIA) group.
The study will assess the efficacy and safety of intradermal acupuncture for MDD.
In addition, investigator will explore the possible cerebral mechanisms by which IA exerts its antidepressant effects.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- the Third affiliated hospital of Zhejiang Chinese Medical university [Recruiting]
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 60 years (Adult)
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Patients diagnosed with MDD according to the International Classification of Disease-10 (ICD-10);
- Aged between 18 and 60 years (no limitation on gender);
- Administration of SSRIs;
- Patients undergoing MRI and MRS should be right-handed and free of traumatic brain injury, claustrophobia or metal implants;
- Written informed consent is obtained by the person or guardian.
Exclusion Criteria:
- ICD-10 diagnoses: schizophrenia, bipolar disorder, manic episode or other psychotic disorders; alcohol and drug addiction;
- Significant skin lesions, severe allergic diseases, tumors, and severe or unstable internal diseases involving the cardiovascular, digestive, endocrine, or hematological system;
- Acute suicidal tendency;
- Allergy to adhesive tape and fear of intradermal acupuncture;
- Pregnancy and lactation;
- Mental retardation and difficulty cooperating with doctors.
- Participating in other clinical trials.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Waiting list group
This group will include 40 patients with MDD who will be treated with oral SSRIs only, the dosage of which will be determined by the psychiatrist.
At the end of this trial, patients could choose 6 weeks' intradermal acupuncture treatments free of charge.
|
SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.
Once daily for the duration of the trial.
Other Names:
|
Sham Comparator: SIA group
This group will include 40 patients with MDD who will be treated with sham intradermal acupuncture (SIA) combined with SSRIs.
Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
|
SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.
Once daily for the duration of the trial.
Other Names:
This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7).
The SIA will use the same size, colour and material as the AIA with a thin silicone pad in the middle instead of the needle body.
SIA will be attached to the acupoints and retained for 72 hours, removed and rested for one day.
A total of 10 sessions will be performed over a period of 6 weeks.
Other Names:
|
Experimental: AIA group
This group will include 40 patients with MDD who will be treated with active intradermal acupuncture (AIA) combined with SSRIs.
Acupoints related to MDD will be stimulated by acupuncturists and the dosage of oral SSRIs will be determined by the psychiatrist.
|
SSRIs antidepressants, including fluoxetine, paroxetine, sertraline, citalopram, etc., will be administered at oral doses determined by the psychiatrist.
Once daily for the duration of the trial.
Other Names:
This study will select 4 acupoints (all taken bilaterally) commonly used to treat MDD, namely Taichong (LR3), Neiguan (PC6), Sanyinjiao (SP6) and Shenmen (HT7).
Depending on acupoints' location, a φ0.20*1.5mm
or φ0.20*1.2mm
AIA will be selected.
Press the AIA to insert it vertically into the acupoint and retain it in the skin.
AIA will be retained for 72 hours with a day's rest after removal.
During the period of needle retention, participants will be instructed to press the AIA 3-4 times a day for approximately 1 minute each time, with as much stimulation as the patient can tolerate, at intervals of approximately 4 hours.
A total of 10 sessions will be performed over a period of 6 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Hamilton Depression Scale-17 (HAMD-17) Scores
Time Frame: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The HAMD scale is the most commonly used in the clinical assessment of depression, including 17 items.
The higher the score, the more severe the depression.
0-7 means no depressive symptoms, 8-17 means mild depression, 18-24 was divided into moderate depression, and 25-52 was divided into severe depression.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in the Pittsburgh Sleep Quality Index (PSQI) Scores
Time Frame: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up
|
The PSQI is used to assess the sleep quality of the participant in the last 1 month and consisted of 19 self-rated and 5 other rated items.
The higher the score, the worse the sleep quality.
Sleep quality is divided into 4 levels according to the total score.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up
|
Changes in the Self-Rating Depression Scale (SDS) Scores
Time Frame: Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
The standard score is the total of all scores multiplied by 1.25 to the nearest whole number on this scale, which has 20 questions.
A standard score below 50 is normal; 50-60 is mild depression; 61-70 is moderate depression; 70 or more is severe depression.
|
Baseline, 3 weeks after treatment, 6 weeks after treatment, at 4-week follow-up.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse Events
Time Frame: Up to 10 weeks
|
Adverse events such as bleeding, haematoma, or unbearable pain caused by the needle, as well as drug-induced nausea, vomiting or dizziness, will all be recorded.
|
Up to 10 weeks
|
Evaluation of acupuncture compliance
Time Frame: 6 weeks after treatment
|
At the end of the acupuncture intervention (end of week 6), compliance will be evaluated with the formula: Compliance Rate = (actual treatment times/total treatment times) *100%.
|
6 weeks after treatment
|
Magnetic resonance imaging (MRI) data acquisition
Time Frame: Baseline
|
Brain MRI will be taken by a 3.0T MRI scanner to analyze the activity function of brain regions, such as the striatum and ventral tegmental area, before and after the acupuncture intervention of patients, and at the baseline of heath controls.
|
Baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Xiaomei Shao, Ph.D, the Third Affiliated Hospital of Zhejiang Chinese Medical University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2022
Primary Completion (Actual)
January 1, 2024
Study Completion (Actual)
January 1, 2024
Study Registration Dates
First Submitted
January 31, 2023
First Submitted That Met QC Criteria
January 31, 2023
First Posted (Actual)
February 9, 2023
Study Record Updates
Last Update Posted (Actual)
February 20, 2024
Last Update Submitted That Met QC Criteria
February 18, 2024
Last Verified
February 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022ZX010-IAM
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Disorder
-
York UniversityCentre for Addiction and Mental HealthSuspendedDisorder, Major DepressiveCanada
-
Shalvata Mental Health CenterUnknownMAjor Depressive DisorderIsrael
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDD)India
-
Repurposed Therapeutics, Inc.Unknown
-
GlaxoSmithKlineCompletedMajor Depressive Disorder (MDD)United States
-
Seasons Biotechnology (Taizhou) Co., Ltd.CompletedMajor Depressive Disorder (MDDIndia
-
Gangnam Severance HospitalCompletedMajor Depressive Disorder(MDD)Korea, Republic of
-
University College, LondonCompletedUnipolar Major Depressive DisorderUnited Kingdom
-
Fundació Institut de Recerca de l'Hospital de la...Fondo de Investigacion SanitariaUnknown
-
AccexibleRecruitingMajor Depressive Disorder (MDD)Spain
Clinical Trials on SSRI
-
Baker Heart Research InstituteNational Health and Medical Research Council, AustraliaUnknown
-
University of Texas Southwestern Medical CenterNational Institute of Mental Health (NIMH)CompletedDepressionUnited States
-
Hoffmann-La RocheCompletedObsessive-Compulsive DisorderUnited States, Canada
-
Shanghai Mental Health CenterUnknownMajor Depressive Disorder
-
University of Illinois at ChicagoNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)CompletedInternalizing Psychopathologies (IPs) Depression and AnxietyUnited States
-
National Institute of Mental Health (NIMH)WithdrawnDepression | Major Depression | Unipolar Depression | Anxiety Disorder
-
RenJi HospitalUnknown
-
University of California, San FranciscoNational Institute of Mental Health (NIMH); National Institutes of Health (NIH)Recruiting
-
Janssen-Cilag Ltd.Active, not recruitingDepressive Disorder, MajorTaiwan, Turkey, Malaysia, Germany, Czechia, Korea, Republic of, Poland, Hungary, Argentina, Belgium, Bulgaria, Finland, Greece, South Africa
-
Inje UniversityUnknownMajor Depressive DisorderKorea, Republic of